- NASDAQ:BNTX continues its surge as it gains 7.60% on Tuesday.
- BioNTech and Pfizer announced a 90% efficacy for their COVID-19 vaccine candidate trials.
- With up to 1.3 billion doses being produced for 2021, BNTX is a long-term pay in the biotech field.
NASDAQ:BNTX did well to partner with American pharmaceutical giant Pfizer (NYSE:PFE) as the two firms have produced one of the most historic vaccines of our lifetime. BioNTech’s stock continued its gains on Tuesday, adding a further 7.60% as investors piled into the German company, a day after its game-changing announcement. Shares of BNTX are now up nearly 500% for the year and investors who took a chance on the little known biotech company back in March when the partnership with Pfizer was first announced are celebrating the successes of the vaccine candidate BNT162b2.
It seems like great timing as the global financial markets were already rallying around the likelihood of a Joe Biden administration in the White House, when the Pfizer and BioNTech announcement sent the markets through the roof. Democratic president-elect Biden himself has supported the wearing of masks and pledged that the first thing he will do when taking the office is to tackle the coronavirus pandemic in America. Having 1.3 billion doses of BNT162b2 ready for distribution in 2021 will definitely help with that.
BNTX Stock Forecast
While having an FDA approved vaccine on the horizon has provided investors and the world with optimism, the world is still months away from having widespread access. BioNTech also has a series of oncology treatments, with twelve different candidates currently at some stage of clinical testing. Despite all of these, BioNTech reported a nice jump in third quarter revenues that are clearly connected to its work with Pfizer, and this could spike even more next quarter, as the companies announced they would be seeking FDA approvals as early as next week.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD declines below 1.0700 as USD recovery continues
EUR/USD lost its traction and declined below 1.0700 after spending the first half of the day in a tight channel. The US Dollar extends its recovery following the strong Unit Labor Costs data and weighs on the pair ahead of Friday's jobs report.
GBP/USD struggles to hold above 1.2500
GBP/USD turned south and dropped below 1.2500 in the American session on Thursday. The US Dollar continues to push higher following the Fed-inspired decline on Wednesday and doesn't allow the pair to regain its traction.
Gold stuck around $2,300 as market players lack directional conviction
Gold extended its daily slide and dropped below $2,290 in the second half of the day on Thursday. The benchmark 10-year US Treasury bond yield erased its daily losses after US data, causing XAU/USD to stretch lower ahead of Friday's US jobs data.
Top 3 Price Prediction BTC, ETH, XRP: Altcoins to pump once BTC bottoms out, slow grind up for now
Bitcoin reclaiming above $59,200 would hint that BTC has already bottomed out, setting the tone for a run north. Ethereum holding above $2,900 keeps a bullish reversal pattern viable despite falling momentum. Ripple coils up for a move north as XRP bulls defend $0.5000.
Happy Apple day
Apple is due to report Q1 results today after the bell. Expectations are soft given that Apple’s Chinese business got a major hit in Q1 as competitors increased their market share against the giant Apple.